Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer
07:30 EST 11 Jan 2013 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq:
ARQL) today announced the top-line results of a randomized Phase 2
signal generation trial of tivantinib (ARQ 197) used in combination with
irinotecan and cetu...
Other Sources for this Article
Daiichi Sankyo, Inc. (US)
Tara Camp, 973-944-2393
or
ArQule,
Inc.
William B. Boni, 781-994-0300
VP, Investor
Relations/Corp. Communications
More From BioPortfolio on "Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
